Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 8, Number 12—December 2002
Perspective

Dengue Hemorrhagic Fever in Infants: Research Opportunities Ignored

Scott B. Halstead*Comments to Author , Nguyen Trong Lan†, Thein Thein Myint‡, Than Nu Shwe‡, Ananda Nisalak§, Siripen Kalyanarooj¶, Suchitra Nimmannitya¶, Soegeng Soegijanto#, David W. Vaughn§, and Timothy P. Endy§
Author affiliations: *Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA; †Children’s Hospital No. 1, Ho Chi Minh City, Vietnam; ‡Yangon Children’s Hospital, Yangon, Myanmar;; §Armed Forces Research Institute of the Medical Sciences, Bangkok, Thailand; ¶Queen Sirikit National Institute of Child Health, Bangkok, Thailand; #Dr. Soetomo Hospital, Airlangga University Medical School, Surabaya, Indonesia;

Main Article

Figure 5

Relationship between the age distributions of infants hospitalized for dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) and the protective and infection-enhancing effects of maternal dengue antibodies. Shown are mean age specific hospitalization rate/1,000 for Bangkok and Thonburi, 1962–1964 (see Figure 1). At birth, antibodies are at protective concentrations. With the passage of time, maternal immunoglobulin G antibodies are catabolized to concentrations that result in antibody-dependent enhancement (ADE) of infections. By the end of the first year of life, ADE antibodies are catabolized to concentrations below the ADE threshold, and DHF/DSS cases disappear.

Figure 5. Relationship between the age distributions of infants hospitalized for dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) and the protective and infection-enhancing effects of maternal dengue antibodies. Shown are mean age specific hospitalization rate/1,000 for Bangkok and Thonburi, 1962–1964 (see Figure 1). At birth, antibodies are at protective concentrations. With the passage of time, maternal immunoglobulin G antibodies are catabolized to concentrations that result in antibody-dependent enhancement (ADE) of infections. By the end of the first year of life, ADE antibodies are catabolized to concentrations below the ADE threshold, and DHF/DSS cases disappear.

Main Article

Page created: July 19, 2010
Page updated: July 19, 2010
Page reviewed: July 19, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external